The John Paul II Medical Research Institute was founded in 2007 by Dr. Alan Moy. It is a secular organization that is grounded in a pro-life bioethic that respects the dignity of every human life. The Institute has chosen a name honoring the late pontiff, blessed John Paul II, that clearly demonstrates this unwavering commitment to the culture of life. More than 300 institutes and organizations engage in and support human embryonic stem cell research. The John Paul II Medical Research Institute advocates for medical research that recognizes the dignity of human life from the moment of conception to natural death. Also, the Institute advocates a new paradigm in research to address deficiencies in medical research and unmet medical needs.
The John Paul II Medical Research Institute (JP2MRI) focuses on the most ethical and cost-effective way of conducting medical research to help develop therapies and cures for a variety of diseases. Most diseases share a common technical requirement to create therapies. The Institute’s research focuses on these common technical requirements by recruiting patients to procure tissue to develop stem cells and cancer cells for medical research.
The Institute differentiates itself from other research organizations in the following manner:
1. We do NOT support embryonic stem cell research. We support research that is pro-life driven.
2. We devote more than half of our budget towards medical research, which is far greater than most established foundations.
The John Paul II Medical Research Institute (JP2MRI) seeks to find cures and therapies exclusively using a variety of adult stem cells and induced pluripotent stem cells. The Institute does not engage in embryonic stem cell research of any kind. JP2MRI develops preclinical research technologies that will broadly advance drug discovery and regenerative medicine for many diseases. In addition, the Institute will engage in educational outreach to increase the number of scientists and future medical practitioners who will work with adult stem cells, always with an emphasis on medical bioethics that is consistent with the dignity of human life.
General Stem Cell Education
Stem cell research is the most debated, controversial and misrepresented research. It is important that the public is educated on the key scientific, bioethical and political facts surrounding this research in order to make an informed decision on this area. The following statements are answers to important questions related to stem cell research and potential therapies.
What are Stem Cells?
Answer: Stem cells are unique cells that give rise to a cell that produces self-renewal and another cell that has the ability to differentiate into a specialized cell like a nervous tissue, heart tissue, and pancreatic tissue.
Are all Stem Cells the same?
Answer: No. There are many different types of stem cells. Stem cells come from a variety of different sources: embryos, fetuses, umbilical cords, placenta and adult tissues. Stem cells are categorized into three categories: pluripotent, multipotent and unipotent. Each class and type of stem cell has advantages and disadvantages. After fertilization between an egg (or ovum) and sperm, an embryo is formed and undergoes cell division to form a blastocyst, a small cluster of stem cells. These primitive stem cells ultimately develop into three germ layers or subcategories of tissues: endoderm, mesoderm, and ectoderm. From each of these separate germ layers, there is further differentiation into the ultimate specialized tissue.
Endoderm germ cells ultimately differentiate into: liver, gut and lung tissue.
Mesoderm germ cells ultimately differentiate into: blood, muscle, bone, cartilage, heart, kidney and pancreas tissue.
Ectoderm germ cells ultimately differentiate into: nervous tissue and skin tissue.
Pluripotent stem cells are stem cells that can differentiate into tissues from all three germ layers.
Embryonic stem cells are the most well-known and accepted type of pluripotent stem cell.
In 1998 James Thompson from the University of Wisconsin derived embryonic stem cells from fertilized embryos discarded from in vitro fertilization procedures. Subsequent research has shown that embryonic stem cells are pluripotent and have grown into a variety of different tissue under cultured conditions. Since an embryonic stem cell requires the destruction of a human embryo to produce such a cell line, this type of research is considered ethically and morally controversial.
Since Dr. Thompson’s report, Dr. Shinya Yamanaka from the Kyoto University received the 2012 Nobel Prize in Medicine for producing Induced Pluripotent Stem (IPS) cells, which are pluripotent stem cells that avoid the use of human embryos. In this process, adult cells are genetically reprogrammed backward into a very primitive embryonic-like stem cell with the same characteristics as an embryonic stem cell – sparing the need to use and destroy a human embryo.
Multipotent stem cells are stem cells that can differentiate into tissues from 1-2 germ layers.
Unipotent stem cells are stem cells that can differentiate into tissue from 1 type of germ layer.
Another common terminology is the concept of plasticity. Plasticity refers to the potential of a stem cell to differentiate into a variety of different germ layers. A pluripotent stem cell would be considered the most plastic while unipotent stem cells would represent the least plastic stem cells.
Dr. Kim is the founder and president of Progressive Rehabilitation Medicine which was established in Cedar Rapids, IA in 2005 with the mission of offering advanced non-surgical pain management solutions.
Dr. Kim originally grew up in NJ, attended college at Cornell University in NY, and received his medical degree from Rutgers New Jersey Medical School.
Subsequently, he completed an internal medicine fellowship through John Hopkins University/Sinai Hospital in Baltimore and then his residency training in Physical Medicine and Rehabilitation(PM&R) at Rutgers/Kessler Institute for Rehabilitation which is considered one of the top training programs for this medical specialty.
Dr. Kim served as academic chief resident in his final year of specialization where he gained invaluable insights into the complexity of healthcare systems.
Dr. Kim is board certified by the American Board of Physical Medicine and Rehabilitation and is a Fellow of American Academy of Physical Medicine and Rehabilitation. He has special interests in the non-surgical treatment of spine, sports, and musculoskeletal pain conditions.
Dr. Kim’s Credentials
June 2002-2005 — UMDNJ NEW JERSEY MEDICAL SCHOOL, Newark, NJ
KESSLER INSTITUTE FOR REHABILITATION, West Orange, NJ
(Resident physician in Physical Medicine and Rehabilitation)
2004-2005 — Academic Chief Resident
June 2001-2002 — JOHNS HOPKINS UNIVERSITY/SINAI HOSPITAL, Baltimore, MD (Fellowship in General Internal Medicine)
May 2001 — UMDNJ NEW JERSEY MEDICAL SCHOOL, Newark, NJ (Doctorate of Medicine)
May 1993-1997 — CORNELL UNIVERSITY, COLLEGE OF ARTS AND SCIENCES, Ithaca, NY (Major: Chemistry; Concentration: International Relations)
June 2006-2016 — Diplomate of American Board of Physical Medicine and Rehabilitation
April 2017-Present — Medical Director – Mercy Inpatient Rehabilitation Unit Center of Excellence
August 2005-Present — President – Progressive Rehabilitation Medicine, PLC
May 2007-2010 — Medical Director – St. Luke’s Human Motion Institute – Spine Care
November 2013 — Present – Surgery Center of Cedar Rapids Chronic Tendon Pain Center of Excellence (TENEX Specialist)
Musculoskeletal, spine, sports and occupational medicine
Diagnostic and Interventional Musculoskeletal Ultrasound
Neurodiagnostics testing: EMG/NCV
Neurorehabilitation: botulinum toxin injections, alcohol neurolysis, Intrathecal baclofen pump management
Regenerative Orthopedic Medicine: platelet-rich plasma, deep tissue laser therapy, non-surgical spinal decompression
Independent Medical Examinations
American Academy of Physical Medicine and Rehabilitation
American Academy of Neuromuscular and Electrodiagnostic Medicine
American Institute of Ultrasound in Medicine
Neurorehabilitation Preceptor Program
Leaders in Orthopedic Stem Cell Therapy